GE Healthcare has rolled out its Invenia 2.0 automated breast ultrasound (ABUS) system in the U.S.
The device has received clearance from the U.S. Food and Drug Administration (FDA) as a supplemental ultrasound breast screening technology designed to detect cancer in dense breast tissue. GE launched the first Invenia in 2014.
Invenia ABUS 2.0 features the cSound Imageformer software-based graphics processor, which is designed to collect significantly more data for use in every image. No image manipulation is required, so image quality is consistent among operators.
The device also includes the Reverse Curve transducer, which is shaped to the natural contour of the breast for better patient comfort and scanning coverage. The transducer has a 15-cm field-of-view for improved positioning and maintains even compression throughout the scan.
Finally, exams can be customized with programmable scan protocols, adjustable scan depths, and compression levels.
